[ad_1]
Biocon's share price lost more than 1% on Monday. The USFDA conducted a pre-inspection at the company's new solid oral dosage form manufacturing facility at Biocon Park
. The inspection took place from November 5 to 9, 2018.
The audit was completed without any observations or Form 483 issued. .
The successful audit of this site reflects our strong commitment to quality and GMP compliance, said Spokesperson.
On September 26, 2018 and November 14, 2017, the action reached its highest level in 52 weeks, or 718.35 rupees and its lowest level in 52 weeks, on November 14, 2017.
73.31 percent above its 52-week low.
For more information on the market, click here
[ad_2]
Source link
